Evidence map›Paper›PMID 35156002›Full record

ArticleJAMIA open2022

ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trails.

Gustavo A Jimenez-Maggiora, Stefania Bruschi, Hongmei Qiu, Jia-Shing So, Paul S Aisen

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMIA open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Gustavo A Jimenez-MaggioraAlzheimer's Therapeutic Research Institute, Department of Neurology, Keck School of Medicine of USC, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-9745-5121
Stefania BruschiAlzheimer's Therapeutic Research Institute, Department of Neurology, Keck School of Medicine of USC, Los Angeles, California, USA.
Hongmei QiuAlzheimer's Therapeutic Research Institute, Department of Neurology, Keck School of Medicine of USC, Los Angeles, California, USA.
Jia-Shing SoAlzheimer's Therapeutic Research Institute, Department of Neurology, Keck School of Medicine of USC, Los Angeles, California, USA.
Paul S AisenAlzheimer's Therapeutic Research Institute, Department of Neurology, Keck School of Medicine of USC, Los Angeles, California, USA.

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
NIA NIH HHS U24 AG057437
6 · The paper itself

Abstract

objectiveThe Alzheimer's Therapeutic Research Institute (ATRI) developed a novel clinical data management system, the ATRI electronic data capture system (ATRI EDC), to address the complex regulatory, operational, and data requirements that arise in the conduct of multicenter Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRDs) clinical trials. We describe the system, its utility, and the broader implications for the field of clinical trials and clinical research informatics. MATERIALS AND

methodsThe ATRI EDC system was developed, tested, and validated using community-based agile software development methods and cloud-native single-page application design principles. It offers an increasing number of application modules, supports a high degree of study-specific configuration, and empowers study teams to effectively communicate and collaborate on the accurate and timely completion of study activities.

resultsTo date, the ATRI EDC system supports 10 clinical studies, collecting study data for 4596 participants. Three case descriptions further illustrate how the system's capabilities support diverse study-specific requirements. DISCUSSION: The ATRI EDC system has several advantages: its modular capabilities can accommodate rapidly evolving research designs and technologies; its community-based agile development approach and community-friendly licensing model encourage collaboration per the principles of open science; finally, with continued development and community building efforts, the system has the potential to facilitate the effective conduct of clinical studies beyond the field of AD/ADRD.

conclusionBy effectively addressing the requirements of multicenter AD/ADRD studies, the ATRI EDC system supports ATRI's scientific mission of rigorously testing new AD/ADRD therapies and facilitating the effective conduct of multicenter clinical studies.

Indexed as

Alzheimer diseaseclinical research informaticsclinical trialsdata managementremote electronic data capture

Identifiers

PMID35156002
PMCPMC8826990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.